Pharmacy

A new report highlights physical, social, and economic challenges of migraine.

UnitedHealthcare will pass on pharmacy discounts directly to some consumers, signaling the next wave of disruption in healthcare, say industry watchers.

There is no cure for HIV, but with proper medical treatment, the disease can be controlled.

The Cigna-Express Scripts deal may signal a move to more vertical and horizontal healthcare deals. Here’s what else it means.

A new study has eye-opening findings on the use of buprenorphine induction in an opioid-dependent population with commercial benefit coverage.

A lack of national standards and less than optimal oversight of many inpatient, opioid addiction rehabilitation programs is raising questions about the level of services, personnel, and quality of care many patients are receiving.

Genetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.

Switzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.

Eye-opening research by NTT DATA Services sheds light on healthcare consumer satisfaction with virtual versus human agents.

Hospitals are always looking for ways to reduce readmission rates. They may have an unusual ally in a quality control system originally developed in Europe for the manufacturing sector. Read more about it.

Retail drug chain giant Walgreens made a takeover approach to drug distributor AmerisourceBergen. Here’s what industry watchers want you to know about it.

A new study has eye-opening findings on the use of buprenorphine induction in an opioid-dependent population with commercial benefit coverage

John R. Washlick, Buchanan, Ingersoll & Rooney, and expert in healthcare system transactions and market consolidation, talks to Managed Healthcare Executive about healthcare spin-offs, what that means for the future of mergers and acquisitions, and advice for healthcare executives.

A Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.

Here are three strategies to navigate toward next-generation care management and increase member engagement in the process

Understanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.

Treatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.

Shift represents growing understanding of value of genetic testing for cancers. Find out who is receiving the test and why.

Corporate giants Amazon, Berkshire Hathaway, and JPMorgan Chase, partner to shake things up in U.S. employee healthcare.

Reducing readmissions for chronic obstructive pulmonary disease (COPD) is an ongoing challenge for healthcare systems. Here’s how one is successful.

The flu epidemic is taking a toll on the U.S. healthcare system. Here's how health insurers can curtail spending on flu care.

The impact of VBRs on outcomes, VBRs versus other healthcare reimbursement initiatives, and VBR successes and failures. Pfizer’s Robert Popovian, PharmD, weighs in.

From State-led programs to innovative pharmacist-hospital partnerships, these programs are fighting to quell the epidemic.

How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.

Oncology Institute’s Dawn Holcombe, MBA, FACMPE, ACHE, shares her views on the OCM program, what CAR T-cell therapy means for the future of reimbursement, and some epic predictions.